Processing

Please wait...

Settings

Settings

1. WO2020005496 - SPECIFIC BIFUNCTIONAL BY-001 (ACTIVE COMPOSITION OF HOMOMULTIMER OF CHIMERIC PROTEIN PD-L1 / FC-GAMMA1) DOWN REGULATES THE ACTIVATION OF HUMAN IMMUNE CELLS AND THE USE THEREOF

Publication Number WO/2020/005496
Publication Date 02.01.2020
International Application No. PCT/US2019/035818
International Filing Date 06.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
04
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A61K 38/17 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
A61K 47/68 (2017.01)
A61P 1/04 (2006.01)
A61P 3/10 (2006.01)
CPC
A61K 35/17
A61K 38/00
A61K 47/68
A61P 37/06
C07K 14/70532
C07K 14/70535
Applicants
  • LU, Yunbiao [US/US]; US
Inventors
  • LU, Yunbiao; US
Priority Data
16/190,64114.11.2018US
62/689,21424.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SPECIFIC BIFUNCTIONAL BY-001 (ACTIVE COMPOSITION OF HOMOMULTIMER OF CHIMERIC PROTEIN PD-L1 / FC-GAMMA1) DOWN REGULATES THE ACTIVATION OF HUMAN IMMUNE CELLS AND THE USE THEREOF
(FR) RÉGULATION À LA BAISSE DE L'ACTIVATION DE CELLULES IMMUNES HUMAINES PAR BY-001 (COMPOSITION ACTIVE D'HOMOMULTIMÈRE DE LA PROTÉINE CHIMÉRIQUE PD-L1/FC-GAMMA1) BIFONCTIONNEL SPÉCIFIQUE ET UTILISATION CORRESPONDANTE
Abstract
(EN)
The present invention provides an active form (BY-001) of a homomultimeric chimeric protein PD-L1 / Fc-gamma1, which may have a composition of 25% dimer, 30% tetramer and 45% hexamer. BY-001 consists of two distinct functional domains at the aggregated state, one is the extracellular domain of PD-L1 and another one is the IgG1 Fc region. Accordingly, the first functional domain of PD-L1 at its aggregated state is more effective in suppressing the activity of CD3+ and CD28+ T cells; while, on the other hand, the second functional domain of FC-gamma1 at its aggregated state exerts only the suppressive effects on the immune cell bearing the Fc-gamma receptors. Thus, the features provided in present invention indicate that BY-001 regulates the functions of immune cells subsets that are responsible for the peripheral immune tolerance, which makes BY-001 potential to help restore or maintain the peripheral immune tolerance in patients with autoimmune diseases or in recipients of allografts.
(FR)
La présente invention concerne une forme active (BY-001) d'une protéine chimérique homomultimère PD-L1/Fc-gamma1, qui peut avoir une composition de 25 % de dimère, 30 % de tétramère et 45 % d'hexamère. BY-001 est constitué de deux domaines fonctionnels distincts à l'état agrégé, l'un est le domaine extracellulaire de PD-L1 et l'autre est la région Fc d'IgG1. Par conséquent, le premier domaine fonctionnel de PD-L1 dans son état agrégé est plus efficace dans la suppression de l'activité de cellules CD3+ et CD28+ T ; tandis que, d'autre part, le deuxième domaine fonctionnel de FC-gamma1 dans son état agrégé n'exerce que les effets suppresseurs sur la cellule immune portant les récepteurs Fc-gamma. Ainsi, les caractéristiques obtenues dans la présente invention indiquent que BY-001 régule les fonctions de sous-ensembles de cellules immunes qui sont responsables de la tolérance immune périphérique, grâce à quoi le BY-001 présente le potentiel d'aider à restaurer ou maintenir la tolérance immune périphérique chez des patients atteints de maladies auto-immunes ou chez des receveurs d'allogreffes.
Latest bibliographic data on file with the International Bureau